Hepatology And Advanced Liver Disease - USMLE Step 2

SECTION 1

Historical Context & Motivation

The liver has been recognized as a vital organ since antiquity, with Hippocrates describing jaundice and ascites as harbingers of severe disease. However, a systematic understanding of hepatology — the study of the liver, gallbladder, biliary tree, and pancreas — did not emerge until the twentieth century, when advances in histopathology, virology, and transplant surgery converged to create a distinct clinical discipline. Understanding the historical trajectory of hepatology is essential for appreciating why modern management of advanced liver disease rests on a complex interplay of medical, surgical, and interventional strategies.

1819 • Laennec Describes Cirrhosis

René Laennec coins the term "cirrhosis" (from Greek kirrhos, meaning tawny) to describe the nodular, fibrotic liver he observed at autopsy, establishing the anatomic foundation of chronic liver disease.

1958 • Discovery of the Australia Antigen

Baruch Blumberg identifies the Australia antigen (HBsAg), ultimately linking it to hepatitis B virus and earning the Nobel Prize. This discovery launched the era of viral hepatitis characterization.

1967 • First Successful Liver Transplant

Thomas Starzl performs the first successful orthotopic liver transplant in a human, transforming end-stage liver disease from an inevitably fatal condition into a potentially curable one.

1989 • Hepatitis C Virus Identified

Michael Houghton and colleagues identify the hepatitis C virus using molecular cloning techniques, enabling serologic screening and eventually curative direct-acting antiviral therapy.

2013 • Direct-Acting Antivirals Revolutionize HCV Treatment

Sofosbuvir and other DAAs achieve sustained virologic response rates exceeding 95%, fundamentally changing the natural history of chronic hepatitis C and reducing the need for liver transplantation.

Despite these remarkable advances, liver disease remains a leading cause of morbidity and mortality worldwide. The central challenge in hepatology today is the early recognition and management of decompensated cirrhosis and its complications — including variceal hemorrhage, ascites, hepatic encephalopathy, and hepatorenal syndrome — while determining the optimal timing for liver transplant referral. This lesson examines the full spectrum of advanced liver disease as it pertains to clinical decision-making on USMLE Step 2.

SECTION 2

Core Principles of Advanced Liver Disease

Advanced liver disease encompasses a continuum from compensated cirrhosis, in which the liver maintains adequate synthetic and metabolic function despite architectural distortion, to decompensated cirrhosis, marked by the development of clinically significant complications. The transition from compensated to decompensated disease represents a critical inflection point, associated with a dramatic decline in survival from a median of over 12 years to approximately 2 years without transplantation. A firm grasp of the following foundational concepts is essential for clinical reasoning in hepatology.

Portal Hypertension

Increased resistance to portal blood flow (hepatic venous pressure gradient ≥ 10 mmHg is clinically significant) drives the formation of portosystemic collaterals, varices, ascites, and splenomegaly — the hemodynamic engine of decompensation.

Hepatic Synthetic Failure

Progressive loss of hepatocyte mass impairs synthesis of albumin, clotting factors (II, VII, IX, X), and complement proteins. Hypoalbuminemia reduces oncotic pressure, exacerbating edema and ascites, while coagulopathy increases bleeding risk.

Impaired Detoxification

Portosystemic shunting and reduced hepatocyte function lead to accumulation of ammonia and other neurotoxins, producing the clinical syndrome of hepatic encephalopathy ranging from subclinical cognitive impairment to frank coma.

Hyperdynamic Circulation

Splanchnic vasodilation mediated by nitric oxide leads to decreased effective arterial blood volume, triggering compensatory activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system, resulting in sodium and water retention.

Immune Dysfunction (CAID)

Cirrhosis-associated immune dysfunction combines immunodeficiency (impaired opsonization, reduced complement) with systemic inflammation, predisposing patients to infections such as spontaneous bacterial peritonitis (SBP) and increasing mortality.

✦

KEY TAKEAWAY

Think of the cirrhotic liver as a clogged highway interchange. As architectural distortion increases resistance to portal blood flow, traffic (blood) backs up into alternative routes (varices), essential deliveries (synthetic function) are delayed, and the toll booth workers (detoxification enzymes) are overwhelmed. Portal hypertension is the traffic jam — virtually every complication of cirrhosis can be traced back to this central hemodynamic derangement.

SECTION 3

Pathophysiology of Portal Hypertension — Visual Overview

This flowchart illustrates how increased intrahepatic resistance in the cirrhotic liver leads to portal hypertension, which then branches into three major pathways: portosystemic collateral formation (varices), splanchnic vasodilation with subsequent RAAS activation (leading to ascites, hepatorenal syndrome, and dilutional hyponatremia), and congestive splenomegaly. Variceal hemorrhage is shown as a direct consequence of collateral vessel formation.

The diagram above captures the central hemodynamic cascade of advanced liver disease. At the top, architectural distortion of the cirrhotic liver increases intrahepatic vascular resistance, elevating the hepatic venous pressure gradient (HVPG). When HVPG reaches or exceeds 10 mmHg, portal hypertension becomes clinically significant, manifesting as varices and ascites. At ≥ 12 mmHg, the risk of variceal hemorrhage escalates substantially. The right branch of the diagram highlights splanchnic vasodilation — driven primarily by increased nitric oxide production — which reduces effective arterial blood volume and triggers a neurohumoral cascade through the RAAS and sympathetic nervous system. This cascade underlies the three most common complications seen on USMLE Step 2 vignettes: ascites, hepatorenal syndrome (HRS), and dilutional hyponatremia.

SECTION 4

Scoring Systems & Prognostic Framework

Quantifying the severity of liver disease is critical for guiding management decisions, particularly transplant listing priority. Two scoring systems dominate clinical practice and are frequently tested on USMLE Step 2: the Child-Turcotte-Pugh (CTP) score and the Model for End-Stage Liver Disease (MELD) score. While you are unlikely to be asked to calculate MELD from scratch, understanding the variables and their prognostic implications is essential.

MELD SCORE

MELD = 3.78 × ln(Bilirubin) + 11.2 × ln(INR) + 9.57 × ln(Creatinine) + 6.43

Where bilirubin and creatinine are measured in mg/dL. All values < 1.0 are rounded up to 1.0 to prevent negative logarithmic values. The MELD score predicts 90-day mortality and is used for organ allocation priority by UNOS. MELD-Na incorporates serum sodium: MELD-Na = MELD + 1.32 × (137 − Na) − 0.033 × MELD × (137 − Na).

CTP Parameter	1 Point	2 Points	3 Points
Bilirubin (mg/dL)	< 2	2–3	> 3
Albumin (g/dL)	> 3.5	2.8–3.5	< 2.8
INR	< 1.7	1.7–2.3	> 2.3
Ascites	None	Mild / controlled	Moderate–severe
Encephalopathy	None	Grade I–II	Grade III–IV

Child-Turcotte-Pugh classification: Class A = 5–6 points (well-compensated), Class B = 7–9 (significant functional compromise), Class C = 10–15 (decompensated). CTP class C carries a 1-year survival of approximately 45%.

💡

HIGH-YIELD FOR STEP 2

MELD score is used for transplant listing priority, while CTP class is used to estimate perioperative mortality and guide management decisions. A MELD ≥ 15 generally indicates benefit from transplantation. Remember the MELD mnemonic: Bilirubin, INR, Creatinine — BIC ("Big Indicator of Cirrhosis").

SECTION 5

Complications of Cirrhosis — Classification & Management

The complications of cirrhosis represent the most heavily tested content in hepatology for USMLE Step 2. Each complication has a distinct pathophysiology, diagnostic approach, and evidence-based management algorithm. The following diagram and table provide a comprehensive classification framework.

Summary of the six major complications of decompensated cirrhosis, with key diagnostic criteria and first-line management for each. The dashed box at the bottom emphasizes that liver transplantation remains the definitive therapy when medical management fails.

Key Diagnostic & Management Pearls

For variceal hemorrhage, the initial management triad includes IV octreotide (splanchnic vasoconstrictor), proton pump inhibitor, and emergent upper endoscopy with band ligation within 12 hours. A critical and commonly tested detail is the administration of prophylactic antibiotics (ceftriaxone 1 g IV daily for 7 days), which reduces mortality by preventing SBP in the setting of GI bleeding. Primary prophylaxis of varices involves nonselective beta-blockers (NSBB) such as propranolol or nadolol, which reduce portal pressure by decreasing cardiac output (β₁) and allowing unopposed α-mediated splanchnic vasoconstriction (β₂ blockade).

In ascites, the diagnostic paracentesis is paramount. The serum-ascites albumin gradient (SAAG) ≥ 1.1 g/dL confirms portal hypertension as the etiology. Spontaneous bacterial peritonitis is diagnosed by an ascitic fluid absolute polymorphonuclear (PMN) count ≥ 250 cells/mm³ and is treated empirically with cefotaxime (or ceftriaxone) plus IV albumin (1.5 g/kg on day 1 and 1 g/kg on day 3 to prevent HRS). Refractory ascites — defined as ascites unresponsive to maximum-dose diuretics or requiring large-volume paracentesis — is an indication for transjugular intrahepatic portosystemic shunt (TIPS) or transplant evaluation.

For hepatic encephalopathy (HE), the diagnosis is clinical — look for asterixis, altered mental status, and day-night reversal. While serum ammonia levels correlate loosely with disease, they are neither sensitive nor specific enough to confirm the diagnosis, and trending ammonia levels to guide therapy is not recommended. First-line treatment is lactulose, an osmotic laxative that acidifies colonic contents and converts NH₃ to non-absorbable NH₄⁺, titrated to 2–3 soft bowel movements per day. Rifaximin, a non-absorbable antibiotic, is added as adjunctive therapy and is particularly effective for secondary prophylaxis against recurrent episodes.

SECTION 6

Worked Example — Cirrhosis with New-Onset Ascites

Clinical Vignette: 58-Year-Old Man with Abdominal Distension

1
Step 1 — Interpret the Clinical Presentation

A 58-year-old man with a history of alcohol use disorder and known compensated cirrhosis presents with 3 weeks of progressive abdominal distension, bilateral lower extremity edema, and a 5 kg weight gain. Physical examination reveals a distended abdomen with shifting dullness and a fluid wave. His temperature is 38.3°C, and he appears fatigued.

New-onset ascites with low-grade fever in a cirrhotic patient — high clinical suspicion for both portal hypertensive ascites and spontaneous bacterial peritonitis (SBP).
2
Step 2 — Determine the Next Best Step

The single most important next step is a diagnostic paracentesis. This should be performed on all patients with new-onset ascites, any cirrhotic patient admitted to the hospital, and any patient with ascites who develops clinical deterioration (fever, abdominal pain, encephalopathy, renal impairment). Send the fluid for cell count with differential, albumin, total protein, Gram stain, and culture (inoculated at the bedside in blood culture bottles).

Next best step: Diagnostic paracentesis
3
Step 3 — Interpret the Paracentesis Results

Results return: ascitic fluid albumin 0.8 g/dL (serum albumin 3.0 g/dL), PMN count 400 cells/mm³, total protein 1.2 g/dL, Gram stain negative. Calculate the SAAG: 3.0 − 0.8 = 2.2 g/dL. A SAAG ≥ 1.1 g/dL confirms portal hypertension as the cause. The PMN count of 400 cells/mm³ exceeds the threshold of 250, confirming SBP even in the absence of a positive Gram stain.

SAAG = 2.2 g/dL (portal hypertensive ascites confirmed). PMN ≥ 250 → SBP diagnosed.
4
Step 4 — Initiate Appropriate Treatment

Begin empiric antibiotics immediately — cefotaxime 2 g IV every 8 hours (or ceftriaxone 2 g IV daily) for 5 days. Simultaneously administer IV albumin at 1.5 g/kg on day 1 and 1.0 g/kg on day 3 to reduce the risk of hepatorenal syndrome. The albumin infusion is particularly important in patients with creatinine > 1 mg/dL, BUN > 30 mg/dL, or bilirubin > 4 mg/dL.

Treatment: Cefotaxime + IV Albumin → reduces HRS risk and mortality
5
Step 5 — Plan Ongoing Management & Secondary Prophylaxis

After the acute SBP episode resolves, initiate secondary prophylaxis with daily oral norfloxacin (or trimethoprim-sulfamethoxazole). Start diuretic therapy for ascites management: spironolactone 100 mg daily (titrate up to 400 mg) ± furosemide 40 mg daily (titrate up to 160 mg) in a 100:40 ratio. Counsel on sodium restriction (< 2 g/day). Given this patient's decompensated cirrhosis (ascites + SBP), refer for liver transplant evaluation and calculate MELD score.

Secondary SBP prophylaxis: norfloxacin or TMP-SMX. Diuretics: spironolactone ± furosemide. Transplant referral indicated.

SECTION 7

Etiologies of Cirrhosis — Comparison & Diagnosis

Identifying the underlying etiology of cirrhosis is essential for directing cause-specific therapy and, in some cases, reversing fibrosis before decompensation occurs. USMLE Step 2 frequently tests the ability to distinguish between etiologies based on serologic, histologic, and clinical clues.

Etiology	Key Diagnostic Features	Management
Alcohol-associated	AST:ALT > 2:1, elevated GGT, macrocytosis (MCV > 100), CDT. History of heavy alcohol use (> 14 drinks/week in men).	Abstinence (mandatory), nutrition support, corticosteroids for severe alcoholic hepatitis (Maddrey DF ≥ 32).
MASLD / MASH	Metabolic syndrome (obesity, DM2, dyslipidemia), hepatic steatosis on imaging, elevated ALT > AST, exclusion of other etiologies.	Weight loss (≥ 7–10%), exercise, pioglitazone or vitamin E in select patients, GLP-1 RAs under investigation.
Hepatitis B	HBsAg (+), anti-HBc IgG (+), HBV DNA quantifiable. Check HBeAg/anti-HBe for replication status.	Tenofovir or entecavir (nucleos(t)ide analogues). Screen for HCC regardless of cirrhosis status.
Hepatitis C	Anti-HCV (+), HCV RNA (+). Genotype determines DAA regimen selection.	Pan-genotypic DAAs (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) — cure rate > 95%. Continue HCC surveillance even after SVR.
Autoimmune Hepatitis	Elevated IgG, ANA (+), anti-smooth muscle antibody (+). Young women. Interface hepatitis on biopsy.	Prednisone + azathioprine induction, then azathioprine maintenance. Budesonide in non-cirrhotics.
Primary Biliary Cholangitis	Middle-aged women, pruritus, elevated ALP, anti-mitochondrial antibody (AMA) (+), ↑ IgM.	Ursodeoxycholic acid (UDCA) — slows progression. Obeticholic acid for incomplete response.
Hemochromatosis	Elevated transferrin saturation (> 45%), elevated ferritin. HFE gene testing: C282Y homozygote. Bronze diabetes, arthropathy.	Therapeutic phlebotomy targeting ferritin < 50 ng/mL. Screen first-degree relatives.
Wilson Disease	Age < 40, low ceruloplasmin, elevated 24-hr urine copper, Kayser-Fleischer rings, Coombs-negative hemolytic anemia.	D-penicillamine or trientine (copper chelators). Zinc for maintenance. Transplant for fulminant presentation.

Major etiologies of cirrhosis with distinguishing diagnostic features and first-line management. MASLD = metabolic dysfunction-associated steatotic liver disease; MASH = metabolic dysfunction-associated steatohepatitis.

✦

KEY TAKEAWAY

Think of the workup for cirrhosis etiology as an exclusion algorithm — similar to debugging software. You systematically test each module (viral serologies, autoimmune markers, iron studies, ceruloplasmin, metabolic parameters) until you identify the malfunctioning component. In practice, it is critical to test for all etiologies simultaneously, as multiple insults (e.g., MASLD plus alcohol) may coexist and contribute synergistically to fibrosis progression.

SECTION 8

Liver Transplantation & Advanced Considerations

Liver transplantation represents the definitive treatment for end-stage liver disease and is one of the most successful solid organ transplants, with 1-year survival rates exceeding 90% at experienced centers. Understanding the indications, contraindications, and post-transplant management principles is essential for USMLE Step 2. The transition from managing decompensated cirrhosis to transplant evaluation represents a critical juncture in clinical decision-making.

Category	Medical Management	Liver Transplantation
Goal	Manage complications, slow progression, bridge to transplant	Replace the diseased liver entirely; curative for most etiologies
Timing Indicator	Compensated or early decompensated cirrhosis	MELD ≥ 15 (survival benefit), CTP class C, refractory complications, HCC within Milan criteria
Key Limitations	Cannot reverse advanced fibrosis; does not address ongoing portal hypertension	Organ shortage, lifelong immunosuppression, recurrence of primary disease possible (HCV, MASLD, autoimmune)
Contraindications	Drug-specific (e.g., NSAIDs, aminoglycosides in decompensated disease)	Active sepsis, extrahepatic malignancy, severe cardiopulmonary disease, active substance abuse, non-compliance
Post-Intervention	Ongoing surveillance for HCC, variceal screening, nutritional support	Tacrolimus-based immunosuppression, monitor for acute/chronic rejection, infection prophylaxis, cancer screening

Comparison of ongoing medical management versus liver transplantation for advanced liver disease.

Several special indications merit attention. Acute liver failure (ALF) — defined as severe liver injury with coagulopathy (INR ≥ 1.5) and encephalopathy in a patient without pre-existing liver disease — requires emergent transplant evaluation. The most common cause in the United States is acetaminophen toxicity, treated acutely with N-acetylcysteine (NAC). The King's College criteria are used to identify patients with ALF who are unlikely to survive without transplantation. For HCC, patients meeting Milan criteria (single lesion ≤ 5 cm, or up to 3 lesions each ≤ 3 cm, without vascular invasion or extrahepatic disease) receive MELD exception points to facilitate timely transplantation, as their biological MELD may underestimate disease severity.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A patient with known cirrhosis transitions from compensated to decompensated disease. Which of the following best describes the pathophysiologic mechanism most directly responsible for the development of ascites in this patient?

Show answer

The primary mechanism is splanchnic vasodilation driven by increased nitric oxide production in the setting of portal hypertension. This leads to decreased effective arterial blood volume, triggering compensatory activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system. The resulting renal sodium and water retention, combined with hypoalbuminemia (reduced oncotic pressure from impaired hepatic synthetic function) and elevated hydrostatic pressure in the splanchnic capillaries, causes fluid to accumulate in the peritoneal cavity. The key concept is that ascites in cirrhosis is fundamentally a hemodynamic problem driven by portal hypertension, not simply a consequence of low albumin.

Question 2: BASIC CALCULATION

A paracentesis is performed on a 62-year-old woman with new-onset ascites. The serum albumin is 3.4 g/dL and the ascitic fluid albumin is 0.9 g/dL. The ascitic fluid PMN count is 180 cells/mm³. Calculate the SAAG and determine whether this patient has portal hypertensive ascites. Does this patient have SBP?

Show answer

The SAAG is calculated as serum albumin minus ascitic fluid albumin: 3.4 − 0.9 = 2.5 g/dL. A SAAG ≥ 1.1 g/dL indicates portal hypertension as the cause of ascites, so this patient's ascites is portal hypertensive in origin (consistent with cirrhosis, cardiac failure, or Budd-Chiari). Regarding SBP, the diagnostic threshold is an ascitic fluid PMN count ≥ 250 cells/mm³. This patient's PMN count of 180 cells/mm³ does not meet the diagnostic threshold, so SBP is not diagnosed at this time. However, clinical suspicion should remain high, and a repeat paracentesis should be considered if symptoms worsen.

Question 3: INTERMEDIATE

A 55-year-old man with alcoholic cirrhosis is brought to the emergency department after vomiting approximately 500 mL of bright red blood. His heart rate is 118 bpm and blood pressure is 88/52 mmHg. After initiating fluid resuscitation with a restrictive transfusion strategy, list the three key pharmacologic and procedural interventions that should be initiated within the first 12 hours, including one frequently forgotten measure that reduces mortality.

Show answer

The three key interventions are: (1) IV octreotide, a somatostatin analogue that causes splanchnic vasoconstriction and reduces portal pressure, initiated as a 50 μg bolus followed by 50 μg/hr infusion for 3–5 days; (2) emergent upper endoscopy (EGD) within 12 hours for diagnosis and treatment with endoscopic variceal band ligation; and (3) prophylactic antibiotics — ceftriaxone 1 g IV daily for 7 days. The prophylactic antibiotic is the frequently forgotten measure that has been shown to reduce both bacterial infections (particularly SBP) and mortality in cirrhotic patients presenting with GI bleeding. Additionally, blood transfusion should target a hemoglobin of approximately 7 g/dL (restrictive strategy), as overtransfusion can worsen portal hypertension. If bleeding is refractory to endoscopic intervention, TIPS should be considered.

Question 4: APPLIED

A 47-year-old woman with no known liver disease is brought to the hospital obtunded. Her roommate reports that 3 days ago, the patient ingested an unknown quantity of acetaminophen in a suicide attempt. Labs: AST 8,400 U/L, ALT 7,200 U/L, total bilirubin 6.8 mg/dL, INR 4.9, creatinine 2.8 mg/dL, pH 7.22, lactate 8.2 mmol/L. Describe the diagnosis, the immediate treatment, and the prognostic tool used to determine the need for emergent liver transplantation.

Show answer

This patient has acute liver failure (ALF) secondary to acetaminophen overdose, defined by severe hepatocellular injury (markedly elevated transaminases), coagulopathy (INR ≥ 1.5), and encephalopathy in a patient without prior liver disease. The immediate treatment is N-acetylcysteine (NAC), which should be administered regardless of the timing of ingestion, as it provides benefit even in late presentations by improving hepatic perfusion and oxygen delivery. NAC is given as a 72-hour IV protocol (150 mg/kg loading dose, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours). The King's College Criteria for acetaminophen-induced ALF are used to identify patients unlikely to survive without transplantation: an arterial pH < 7.30 after fluid resuscitation, or the combination of grade III/IV encephalopathy, INR > 6.5, and creatinine > 3.4 mg/dL. This patient's pH of 7.22 alone meets King's College criteria and warrants emergent transplant listing.

Question 5: CRITICAL THINKING

A 60-year-old man with MASH cirrhosis (Child-Pugh B, MELD 18) is found to have a 3.5 cm hepatic mass on surveillance ultrasound. Multiphase CT confirms arterial enhancement with portal venous washout. He has well-controlled diabetes and hypertension but no other comorbidities. Discuss whether this patient meets Milan criteria, the rationale for MELD exception points, the recommended definitive treatment, and the continued need for surveillance even if the tumor is successfully treated.

Show answer

This patient has a single 3.5 cm hepatocellular carcinoma (HCC) diagnosed by characteristic imaging findings (arterial enhancement with washout), which does not require biopsy confirmation. He meets Milan criteria (single lesion ≤ 5 cm, no vascular invasion, no extrahepatic disease) and is therefore eligible for liver transplantation. The rationale for MELD exception points is that a patient's biological MELD score (18 in this case) may not accurately reflect their mortality risk, as the HCC can progress beyond Milan criteria while waiting for transplant, rendering the patient ineligible. Exception points are granted to equalize access. While awaiting transplant, locoregional bridging therapies such as transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) should be considered to prevent tumor progression. Even after successful transplantation, continued surveillance is necessary because HCC can recur in the transplanted liver, particularly given the ongoing risk from metabolic syndrome. Additionally, immunosuppressive medications used post-transplant can theoretically promote tumor growth. The patient's underlying MASH may also recur in the allograft, emphasizing the importance of metabolic risk factor management.

SUMMARY

Hepatology And Advanced Liver Disease — Summary

Summary

Advanced liver disease encompasses the continuum from compensated cirrhosis to decompensated cirrhosis, driven by the central hemodynamic derangement of portal hypertension. The major complications — variceal hemorrhage (treat with octreotide + band ligation + prophylactic antibiotics), ascites (diagnose via paracentesis with SAAG ≥ 1.1, treat with spironolactone ± furosemide), SBP (PMN ≥ 250, treat with cefotaxime + IV albumin), hepatic encephalopathy (treat with lactulose ± rifaximin), and hepatorenal syndrome (IV albumin + vasoconstrictors; definitive treatment is transplant) — each follow distinct diagnostic and management algorithms that are high-yield for USMLE Step 2.

Severity is quantified using the Child-Turcotte-Pugh score (guides prognosis and perioperative risk) and the MELD score (determines transplant listing priority using bilirubin, INR, and creatinine). Etiologic workup must be comprehensive, as causes ranging from alcohol and MASLD to viral hepatitis and autoimmune and metabolic diseases each have specific serologic markers and targeted therapies. Liver transplantation remains the definitive treatment for decompensated cirrhosis, with referral indicated at MELD ≥ 15 or the onset of refractory complications. For acute liver failure, N-acetylcysteine is the immediate intervention for acetaminophen toxicity, and the King's College Criteria guide the decision for emergent transplant listing.